Essential Thrombocythemia Market

Essential Thrombocythemia Market:Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030

Market Overview

Essential thrombocythemia is a rare disease in which your body produces excessive blood platelets. Platelets also called thrombocytes are the blood cells responsible for blood clotting. Human blood contains platelets in the range of 150,000 to 450,000 per microliter.

Essential thrombocythemia occurs due to mutation in JAK2, CALR genes. These genes guide in making of proteins that are essential for growth and division of blood cells.

These mutations lead to abnormal hyperactive signalling of a pathway called JAK pathway. Leading to Essential thrombocythemia.

Gene mutations in Essential thrombocythemia are somatic mutations and occur in initial blood forming cells. People with Essential thrombocythemia experience abnormal blood clotting. The abnormal blood clotting is called thrombosis.  

These clots can block blood flow in brain causing stroke. Clots can also move to lungs causing chest pain and difficulty in breathing. Thrombosis can occur in legs leading to leg pain. People with Essential thrombocythemia may experience abnormal bleeding in the form of nosebleeds, bleeding gums or bleeding within gastrointestinal tract.

Many other signs and symptoms include weakness, fatigue headache, burning and ticking sensation on skin. Essential thrombocythemia is more common in people above age of 50 years.

The diagnosis of Essential thrombocythemia is based on blood tests like complete blood count, blood smear investigation, genetic screening and bone marrow testing. Some patients may not show symptoms but have an increased platelets count.

Life expectancy can be normal. Medical treatment for Essential thrombocythemia depends on the severity of the disease. The gold standard treatment for thrombocythemia is Aspirin. It decreases the symptoms caused by increased platelets count.

Other Drugs like hydroxyurea, anagrelide and interferon alfa-2b are also popular in the treatment. Very rarely plateletpheresis that is removal of platelets is done in Essential thrombocythemia. Asymptomatic patients need not require any treatment.

Drug called IMG-7289 is under phase 2 clinical trial for treatment of Essential thrombocythemia.  Essential thrombocythemia affects around 1 to 24 per 1 million people worldwide. The rate of occurrence of essential thrombocythemia in women is 1.5 times higher than men.

North America is the leader in essential thrombocythemia drug market. With respect to revenue, the U.S. has a major share of the essential thrombocythemia drugs market especially in North America. The essential thrombocythemia drug market is growing rapidly in Europe due to growing geriatric population.

There is a hope of growth in essential thrombocythemia treatment market in developing countries because of growing health care infrastructure, economic growth advancement, development of the private health care sector. There is also increase in awareness among people in these countries.

Essential thrombocythemia has a Potential for new treatments under development and many are currently being tested. This is the major factor contributing to its market growth.

Increase in prevalence rate of Essential thrombocythemia across the world and increase in geriatric population worldwide and ongoing research and development for Essential thrombocythemia treatment can be major drivers for growth of this market. However, cost of the diagnosis especially genetic screening is a major setback for its market growth.

Some of the key market players in Essential thrombocythemia treatment market are

  • Merck & Co., Incyte Corp,
  • Bayer pharmaceuticals,
  • USV,
  • Teva Pharmaceutical Industries Ltd,
  • Sandoz (Novartis AG),
  • AstraZeneca plc,
  • Pfizer Inc,
  • Bristol Myers Squibb Company,
  • Shire Plc.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2015 - 2019
  • Market Size & Forecast 2020 to 2030
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Essential thrombocythemia market segment

The global market for Essential thrombocythemia is segmented based on the treatment drug type, end user and region

By Treatment drug type:

  • Aspirin
  • Hydroxyurea
  • Anagrelide
  • Interferon

By end-user:

  • Hospitals
  • Research organizations
  • Speciality clinics

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Essential Thrombocythemia Market